Chronic daily administration of oral etoposide.

摘要: Etoposide is a useful antineoplastic drug, but its optimal dose and schedule of administration remain unknown. In small cell lung cancer (SCLC), an intravenous given on 5-day clearly superior to the same over 1 day. The standard has been in range 300 500 mg/m2 divided 3 5 days. Whether this dependency (superiority) extends beyond days We have investigated patients with several refractory neoplasms who were oral etoposide long-term period (21-day cycles) phase trial. maximum tolerated 50 mg/m2/d for 21 major toxicity myelosuppression, which usually resolves by 28 35. Responses seen patients. Phase II trials are under way, it appears that daily more active than schedule. germ tumors, lymphomas, SCLC progressed etoposide. addition, drug may be soft tissue sarcoma. Preliminary results combination chemotherapy cisplatin show good tolerance activity. prove and, as such, incorporated into neoplasms.